Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00335699 |
Recruitment Status :
Completed
First Posted : June 12, 2006
Last Update Posted : December 17, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypercholesterolemia | Drug: Rosuvastatin | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 370 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A 6-Week, Randomised, Open-Label, Parallel Group, Multi-Centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Non-Diabetic Metabolic Syndrome Subjects With Raised LDL-C |
Study Start Date : | August 2005 |
Actual Study Completion Date : | January 2007 |

- The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg in the percentage reduction of LDL-C in Subjects with metabolic syndrome after 6 weeks of treatment.
- The secondary objectives of this study are to compare the effects of rosuvastatin 10mg with atorvastatin 10mg in subjects with metabolic syndrome, after 6weeks of treatment, on:
- Bringing subjects to their established NCEP ATP III target goals for LDL-C
- Bringing subjects to their non-HDL target goal(based on NCEP-ATP III criteria)
- Modifying other lipids and lipid ratios
- Modifying inflammatory markers
- Glucose and insulin resistance
- Safety

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Metabolic syndrome patient; Presence of 3 or more of the following:
- Abdominal obesity (waist circumference): men > 90cm(36 inch), women > 80cm(32 inch)
- Triglycerides ≥ 150 mg/dL (1.70 mmol/L)
- HDL-C: men < 40 mg/dL (1.04 mmol/L), women < 50 mg/dL (1.3 mmol/L)
- BP ≥130/≥85 mmHg or subject receiving anti-hypertensive treatment
- Fasting blood glucose 110 mg dL (6.11 mmol/L) - 125 mg/dL (6.94 mmol.L)
-
Elevated LDL-C concentrations reported within 4 weeks of visit 1 as follows;
- ≥ 130 mg/dL (3.36 mmol/L) to < 220 mg/dL (5.69 mmol/L) in statin naive subjects (subjects who have not taken any lipid-lowering therapy known to affect LDL-C in the 4 weeks prior to visit 1)
- ≥ 100 mg/dL (2.59 mmol/L) to < 160 mg/dL (4.14 mmol/L) in subjects who have taken a lipid lowering drug(s) within 4 weeks of visit 1
- Triglyceride levels < 400 mg/dL (4.52 mmol/L)
- Women of childbearing potential should be using a medically acceptable form of chemical or mechanical contraception.
Exclusion Criteria:
- History of known diabetes mellitus
- Use of anti-hyperglycaemic medication.
- History of serious or hypersensitivity reactions to HMG-CoA reductase inhibitors, in particular history of myopathy.
- No CHD or CHD Risk Equivalents and 0-1 Risk factors and Framingham 10-Year risk is <10%.
- History of heterozygous or homozygous familial hypercholesterolaemia or known type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia).
- Active arterial disease such as unstable angina pectoris, myocardial infarction, transient ischaemic attack (TIA), cerebrovascular accident (CVA), coronary artery bypass surgery (CABG) or angioplasty within 2 months prior to entry in the dietary lead in period
- Uncontrolled hypothyroidism defined as thyroid stimulating hormone (TSH) > 1.5 times the upper limit of normal (ULN) at Visit 2 or subjects whose thyroid replacement therapy was initiated within 3 months of entry into dietary lead-in phase.
- Current active liver disease (alanine aminotransferase [ALT] > 2 x ULN) or severe hepatic impairment.
- Unexplained serum CK >3 times ULN (e.g. not due to recent trauma, intramuscular injections, heavy exercise, etc).
- Serum creatinine > 176 umol/L (2.0 mg/dL)
- History of alcohol, or drug, abuse or both.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00335699
Korea, Republic of | |
Research Site | |
DaeGu, Korea, Republic of | |
Research Site | |
IkSan, Korea, Republic of | |
Research Site | |
JeonJu, Korea, Republic of | |
Research Site | |
JinJu, Korea, Republic of | |
Research Site | |
KwangJu, Korea, Republic of | |
Research Site | |
Pusan, Korea, Republic of | |
Research Site | |
Ulsan, Korea, Republic of |
Study Director: | AstraZeneca Korea Medical Director, MD | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00335699 |
Other Study ID Numbers: |
D3560L00053 KREST |
First Posted: | June 12, 2006 Key Record Dates |
Last Update Posted: | December 17, 2007 |
Last Verified: | December 2007 |
Hypercholesterolemia with nondiabetic metabolic syndrome |
Metabolic Syndrome Hypercholesterolemia Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders |
Rosuvastatin Calcium Anticholesteremic Agents Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Enzyme Inhibitors |